Individualized mRNA Cancer Immunotherapies
Various Solid Tumors
Phase 2/3Active
Key Facts
About BioNTech
BioNTech SE is a publicly-traded immunotherapy powerhouse founded by scientists and physicians to translate science into survival through innovative mRNA technologies. The company gained global recognition for its COVID-19 vaccine developed with Pfizer and is now applying its mRNA expertise to cancer immunotherapies and other infectious diseases. With over 25 Phase 2 and Phase 3 oncology trials and a €2.10 billion R&D investment planned for 2025, BioNTech is positioning itself as a leader in personalized cancer treatment and next-generation vaccines.
View full company profileTherapeutic Areas
Other Various Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| TEVIMBRA (tislelizumab) | BeOne Medicines | Approved |
| IMA30X Series (ACTengine®) | Immatics | Pre-clinical |
| RP2 / RP2 + nivolumab | Replimune | Phase 1 |
| Bicycle Toxin Conjugates (BTCs) | Bicycle Therapeutics | Preclinical/Discovery |
| Bicycle Radio Conjugates (BRCs) | Bicycle Therapeutics | Preclinical/Discovery |
| Micvotabart pelidotin (MICVO) | Pyxis Oncology | Phase 1 |
| OST-tADC Platform | OS Therapies | Pre-clinical |